Creating Human Beta Cells to Treat Diabetes
Douglas A. Melton, PhD, Harvard University HHMI, Cambridge, summarized a long history of basic research in pursue of functional human beta cells from embryonic stem cells and he has came very close. His advances are now at the levels of comparing two different models to escape graft rejection by the immune system. Stay tune for this incredibly development.
BMI in infancy may predict obesity at age 6.
Research presented at Endo2016 analyzed records of children under the age of 6, including 783 lean children and 480 severely obese children, and found that BMI in children who become severely obese by age 6 began to differ from children who remain normal weight as early as 4 months of age.
Engineered ovary implant restores fertility in mice
Scientists have created a 3D-printed prosthetic ovary, a project that has been presented at ENDO 2016.
Premenopausal Women Who Undergo Radioactive Iodine Therapy For Differentiated Thyroid Cancer May See Sustained Decline In Anti-Mullerian Hormone Levels In First Year Following Treatment Researchers form Israel found that premenopausal women who underwent radioactive iodine therapy for differentiated thyroid cancer saw a sustained decline in anti-Mullerian hormone levels in the first year following treatment, indicating decreased ovarian reserve, according to study data presented at the Endocrine Society meeting.
Hypothyroidism May Increase Risk Of T2DM
New research suggests people with hypothyroidism may be at greater risk for type 2 diabetes even if their thyroid hormone levels are kept within normal range. The findings of the eight-year study were presented at the Endocrine Society’s annual meeting
Functional imaging for Primary Hyperaldosteronism
Andrew Powlson MD from the University of Cambridge presented his experience with 11C-Metomidate PET- CT as an alternative to AVS in the lateralization of primary hyperaldosteronism
Measurement of Hair Cortisol is here to stay.
Elisabeth van Rossum from Erasmus MC, Rotterdam, presented an extensive review on the use of this technology around the world for diagnosing cortisol excess and deficiency.
In the pipeline for the treatment of Cushings disease
Dr Gunter Stalla, from Max Plank Institute, presented data on new strategies to treat Cushings disease. With expanding knowledge regarding glucocorticoid receptors (GCR), the complex GCR- HSP90 has been targeted by HSP90 inhibitors with promising results. He also presented clinical data on the use of Retinoic acid for Cushings disease
Recent advances in laboratory technologies
Data from Mayo Clinic presented by Irina Bancos show the expanding use of Liquid Chromatography High Resolution Mass Spectometry (LCSM) becoming more common in clinical practice with the potential for a better assessment of steroids profile and its use in the differential diagnosis of adrenal diseases
Oral Formulation of GLP-1 Agonist Benefits T2D Patients In Phase 2 Study.
A novel oral formulation of a GLP-1 agonist has shown robust dose-dependent glucose lowering and weight reductions in patients with early T2DM in a phase 2 study. The data for the investigational oral formulation of Novo Nordisk’s semaglutide were presented at the Endocrine Society meeting.